Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
229 results about "Lactobionic acid" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Lactobionic acid (4-O-β-galactopyranosyl-D-gluconic acid) is a sugar acid. It is a disaccharide formed from gluconic acid and galactose. It can be formed by oxidation of lactose. The carboxylate anion of lactobionic acid is known as lactobionate.
Nanoformulation and methods of use of thyroid receptor beta1 agonists for liver targeting
A composition and an associated method for hepatic targeted delivery of thyroid receptor beta1 (TRβ1) agonist to a liver of a subject. The composition includes hydrophobic nanoparticles, a liver targeting moiety exterior to each nanoparticle and covalently bonded to each nanoparticle, and at least one TRβ1 agonist encapsulated within each nanoparticle. The nanoparticles include chitosan hybrid nanoparticles, amine-modified PLGA nanoparticles, solid lipid nanoparticles, and combinations thereof. The liver targeting moiety includes Glycyrrhetinic acid (GA), Lactobionic acid (LA), or combinations thereof.
Owner:MOUSA SHAKER A
Common carrier material for targeting anticancer drug and gene and preparation and application
InactiveCN102949727AGood biocompatibilityEnhanced Osmotic Retention EffectGenetic material ingredientsInorganic non-active ingredientsTumor targetingResponse control
The invention relates to a common carrier material based on graphene oxide for a targeting anticancer drug and a gene and application and application. Folic acid, lactobionic acid and other tumor cell targeting or liver targeting molecules and part of amino groups of soluble chitosan are connected by amide bonds to prepare a conjugate, the conjugate is then connected with graphene oxide, quaternization is performed by using an epoxy compound with a quaternary ammonium group, and gene molecules are loaded by the quaternizationquaternized part of the chitosan through electrostatic attraction; and then the anticancer drug is loaded by pi-pi conjugates, hydrogen bonds and hydrophobic effects in a non-covalent bond method. By adopting the targeting performance of targeting molecules and effects of graphene oxide of a particular size to enhance penetration and retention in tumor tissues and combining the performance of the graphene oxide for pH response control release of the loaded drug, the drug can be realized released in a tumor cell, an intelligent delivery system for the common carrier of the tumor targeting or liver targeting anticancer drug and the gene is synthesized from the perspective of synergetic medication, and a theoretical basis and a method basis are provided for combined therapy of tumor.
Owner:TIANJIN MEDICAL UNIV
Meso-porous silicon nano-drug carrier with both reduction responsiveness and targeting ability and preparation method thereof
InactiveCN102949728AGood cell compatibilityEasy to operatePowder deliveryMacromolecular non-active ingredientsCell-Extracellular MatrixReceptor
The invention discloses a meso-porous silicon nano-drug carrier with both reduction responsiveness and targeting ability and a preparation method thereof. Firstly, meso-porous silicon nano-particles are prepared with a sol-gel method, and are developed into a nanometer reservoir of drug molecules; then a disulfide bond is introduced into the surface of the meso-porous silicon nanometer reservoir with a simple chemical modification method and is used as a cohesive tie; secondarily, a biocompatible natural extracellular matrix-collagen molecule is creatively fixed to the surface of the meso-porous silicon nanometer reservoir and is developed into a nanometer encapsulator of the meso-porous silicon nanometer reservoir; and finally a lactobionic acid molecule is modified to the surface of a meso-porous silicon / collagen nanometer compounding system and is used as a specificity receptor of a liver cancer cell membrane surface receptor (ASGP-R) so as to construct a meso-porous silicon / collagen-lactobionic acid multifunctional compound type nano-drug carrier system with both cell specificity targeting ability and reducing substance / enzyme responsiveness.
Owner:CHONGQING UNIV
Lyophilized formulations of anti-egfr antibodies
In one embodiment, the present invention provides a stable lyophilized formulation comprising an anti-EGFR antibody, preferably cetuximab; lactobionic acid; and a buffer, preferably histidine. In one preferred embodiment, the present invention provides a stable lyophilized formulation comprising about 50 mg / mL to about 140 mg / mL of ERBITUX?, about 0.125% lactobionic acid, about 25 mM histidine buffer at a pH of about 6.0, about 0.005% Tween 80, and about 1.875% glycine.
Owner:IMCLONE SYSTEMS
Pharmaceutical compositions containing pemetrexed having extended storage stability
ActiveUS20130231357A1Improve long-term stabilityBiocideOrganic active ingredientsDiseasePharmaceutical medicine
Long term storage stable pemetrexed-containing liquid pharmaceutical compositions are disclosed. The compositions can include pemetrexed or pharmaceutically acceptable salts thereof; an antioxidant selected from lipoic acid, dihydrolipoic acid, methionine and mixtures thereof; a chelating agent selected from lactobionic acid, sodium citrate, tribasic and mixtures thereof; and a pharmaceutically acceptable fluid. The pH of the compositions is in a range of about 8 to about 9.5. The pemetrexed-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 227 nm, after at least about 18 months of storage at a temperature of from about 5° C. to about 25° C. Methods of preparing the formulation as well as methods of treatment of pemetrexed-susceptible diseases using the same are also disclosed.
Owner:EAGLE PHARMACEUTICALS INC
Multifunctional nano probe for multimodal images and photothermal therapy of liver cancer and application of multifunctional nano probe
ActiveCN103721271AHigh molecular weightImprove spatial resolutionEnergy modified materialsX-ray constrast preparationsSide effectLight energy
Owner:FUZHOU HOSPITAL FOR INFECTIOUS DISEASE
Prepn and product of oxiracetam powder for injection
InactiveCN1486693AEasy to shapeSimple preparation processOrganic active ingredientsPowder deliveryAlcoholFreeze-drying
The present invention provides one kind of Oxiracetam freeze dried powder for injection and its preparation and product. It is prepared with Oxiracetam, sorbic alcohol or citric acid or lactobionic acid or sodium lactobionate, and water in the weight ratio of 1 to 0.1-2.0 to 1-10 and through weighing Oxiracetam and sorbic alcohol or citric acid or lactobionic acid or sodium lactobionate, dissolving in some container, adding active carbon, heating, filtering to eliminate carbon, regulating pH value, microfiltering, bottling in bacteria-free glass bottle, low temperature freeze drying and sealing.
Owner:HARBIN SANLIAN PHARMA CO LTD
Pharmaceutical compositions containing pemetrexed having extended storage stability
ActiveUS9655898B2Improve long-term stabilityBiocideOrganic active ingredientsDiseaseDihydrolipoic acid
Long term storage stable pemetrexed-containing liquid pharmaceutical compositions are disclosed. The compositions can include pemetrexed or pharmaceutically acceptable salts thereof; an antioxidant selected from lipoic acid, dihydrolipoic acid, methionine and mixtures thereof; a chelating agent selected from lactobionic acid, sodium citrate, tribasic and mixtures thereof; and a pharmaceutically acceptable fluid. The pH of the compositions is in a range of about 8 to about 9.5. The pemetrexed-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 227 nm, after at least about 18 months of storage at a temperature of from about 5° C. to about 25° C. Methods of preparing the formulation as well as methods of treatment of pemetrexed-susceptible diseases using the same are also disclosed.
Owner:EAGLE PHARMACEUTICALS INC
Alcohol free formulation of argatroban
The invention provides an aqueous formulation of argatroban and of related compounds along with a reconstitutable formulation, each of which is substantially, if not totally alcohol free. The formulations are also substantially free, if not totally free, of mono-, di-, and oligo- saccharides. An especially preferred embodiment is a ready-to-use 1 mg / ml injectable dosage form having argatroban, lactobionic acid, and methionine.
Owner:SCIDOSE
Preparation method of hepatoma carcinoma cell targeted molybdenum disulfide drug-loaded nano tablets
InactiveCN104800845ARealize integrationStrong active targetingOrganic active ingredientsEnergy modified materialsDoxorubicin HydrochloridePhotothermal therapy
The invention provides a preparation method of a hepatoma carcinoma cell targeted molybdenum disulfide drug-loaded nano tablets. The preparation method comprises following steps: step 1, molybdenum disulfide nano tablets are obtained via hydro-thermal synthesis; step 2, the molybdenum disulfide nano tablets are added into a gelatin solution, and gelatinized molybdenum disulfide nano tablets are obtained via sufficient reaction; step 3, lactobionic acid, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, and N-hydroxy succinimide are weighed and added into the gelatinized molybdenum disulfide nano tablets so as to obtain lactobionic acid modified molybdenum disulfide nano tablets; and step 4, a doxorubicin hydrochloride aqueous solution is prepared, and the lactobionic acid modified molybdenum disulfide nano tablets obtained via step 3 are added into the doxorubicin hydrochloride aqueous solution, an obtained mixture is stirred for 8 to 24h under vacuum conditions, and is subjected to centrifugalization and washing so as to obtain the hepatoma carcinoma cell targeted molybdenum disulfide drug-loaded nano tablets via collecting. The hepatoma carcinoma cell targeted molybdenum disulfide drug-loaded nano tablets can be used for photothermal therapy and CT imaging, and can be used for realizing combination of diagnosis and treatment of hepatoma carcinoma.
Owner:DONGHUA UNIV
Preparation method and application of fatty acid-trimethyl chitosan polymer modified by lactobionic acid
InactiveCN102863557AGood biocompatibilityPromote degradationPowder deliveryPharmaceutical non-active ingredientsSolubilityPolymer modified
The invention discloses a fatty acid-trimethyl chitosan polymer modified by a lactobionic acid, a preparation method and an application. The fatty acid-trimethyl chitosan polymer modified by the lactobionic acid is an active targeting nano micelle carrier material. A trimethyl chitosan with a good water-solubility is used as a carrier material, the hydrophobic modification is performed by a fatty acid, and then the surface modification is performed by the lactobionic acid to obtain a polymer micelle with the lactobionic acid which mediates tumor tissue target. Harmine is used as a model drug to prepare a drug-loaded nano-micelle in a rubbing and self-assembly mode. A test confirms that the drug loading capacity and encapsulated ratio of the drug-loaded nano-micelle are high, the slow-release property is achieved, cells are effectively taken in through a lactobionic acid receptor pathway, and distribution of drugs on the tumor tissue is increased, so that the curative effect is improved, the toxic and side effect is reduced, and targeted therapy is achieved. The fatty acid-trimethyl chitosan polymer modified by the lactobionic acid, the preparation method and the application provide an ideal novel drug carrier and a preparation form for antitumor drugs with slightly solubility.
Owner:SUZHOU UNIV
Preparation method of hepatoma carcinoma cell-targeted polyamido-amine dendrimer support
InactiveCN102302782AEasy to prepareEasy to operatePharmaceutical non-active ingredientsAntineoplastic agentsDendrimerBiocompatibility Testing
The invention relates to a preparation method of a hepatoma carcinoma cell-targeted polyamido-amine dendrimer support, which comprises the following steps of: (1) modifying a polyamido-amine dendrimer by using fluorescein isothiocyanate to obtain G5.NH2-FI; (2) partially acetylizing the G5.NH2-FI to obtain a product of G5-FI-Ac-NH2 in which an amino-group on the surface of the dendrimer is partially acetylized; (3) modifying the G5-FI-Ac-NH2 by using lactobionic acid to obtain G5-FI-Ac-La with functions of targeting a hepatoma carcinoma cell and tracing by fluorescent. The preparation method provided by the invention is simple and has moderate reaction conditions. Furthermore, a used polymer is an environmental-friendly high polymer material and has a prospect of being industrialized. Thefunctional dendrimer material prepared by the invention is good in biocompatibility and can combine a specific target with the hepatoma carcinoma cell, so that the support can be used in load and targeting delivery of medicines, genes or molecule diagnosing probes.
Owner:DONGHUA UNIV
Cartilage preservation solution
InactiveCN102308787AOvercome mechanical propertiesOvercoming chondrocytesDead animal preservationCartilage cellsFiber
The invention relates to a cartilage preservation solution. Each 1000ml of the preservation solution comprises 20-30mmol of potassium dihydrogen phosphate, 80mmol of histidine or 15mmol of a histidine salt, 75-95mmol of lactobionic acid, 50-70mmol of sucrose, 0.8-1.2mmol of allopurinol, 45-55g of low molecular dextran-40, 45-55mmol of NaCl, 25-35mmol of KCl, 3-7mmol magnesium sulfate, 70-90U of penicillin, 2-4mmol of reduced glutathione, 3-7mmol of adenosine, 2-5g of trehalose, and the balance deionized water, and the pH value of the cartilage preservation solution is 7.33-7.53. The cartilagepreservation solution is packaged, sealed and preserved at 0-4DEG C. By adopting the preservation solution to preserve cartilage tissues, the death speed of cartilage cells is slowed, the activity ofcartilage fibers is maintained, the performance of the cartilage tissues is kept, and the antibiotic property is increased, so the preservation solution has a good preservation effect and a long preservation time on the cartilage tissues, and is in favor of clinic cartilage tissue transplant operations.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Galactosylated chitosan scaffold material for bioartificial liver and preparation method thereof
The invention discloses a galactosylated chitosan scaffold material for a bioartificial liver, which is a galactosylated chitosan biological material with a three-dimensional porous structure which is cross-linked by an oxidized sodium alginate biological crosslinking agent. Its main preparation process: chitosan and lactobionic acid are dissolved in tetramethylethylenediamine / hydrochloric acid mixed solution in an equimolar ratio, and active intermediates are added to activate the reaction to prepare galactosylated chitosan; galactosylated chitosan is dissolved in Acetic acid solution and oxidized sodium alginate are dissolved in ultrapure water, and the two solutions are mixed in a certain proportion to carry out cross-linking reaction. After the reaction is completed, pour it into a mold for molding, freeze-dry to obtain a scaffold material, and then immerse it in sodium hydroxide- The residual acetic acid was removed by ethanol aqueous solution, and then washed by ethanol aqueous solution and freeze-dried twice to obtain the galactosylated chitosan scaffold material cross-linked by oxidized sodium alginate. The galactosylated chitosan scaffold material of the invention has a pore size suitable for the growth of liver cells and good biocompatibility.
Owner:SICHUAN UNIV
Preparation method of antibody-mediated optomagnetic double-mode meso-porous silicon nanoparticles
InactiveCN104027824ASimple methodEasy to operateNMR/MRI constrast preparationsMacromolecular non-active ingredientsSide effectNano composites
The invention belongs to the field of nano composite materials and discloses a preparation method of antibody-mediated optomagnetic double-mode meso-porous silicon nanoparticles. The preparation method comprises the steps of by taking nano ferroferric oxide as a core, applying silicon dioxide to package, labeling by fluorescein isothiocyanate, carrying out surface modification on 3-aminopropyl triethoxysilane to realize amination; then, grafting lactobionic acid by carboxyl-ammonia crosslinking; and finally, activating carboxyl and prostate stem cell antigen (PSCA) antibody. The preparation method disclosed by the invention is simple, and convenient to operate; the obtained nanoparticles have the advantages of active targeting, good biocompatibility, small toxic and side effect, good monodispersity and stability, stable imagnetic and fluorescence performance and the like.
Owner:XIDIAN UNIV
Eye preparation containing lactose-azithromycin
InactiveCN101077352AFix stability issuesSolve usabilityOrganic active ingredientsSenses disorderIrritationMedium chain glycerides
The present invention is one kind of composition for eye medicine preparation. The composition contains antibiotic azithromycin lactobionate as active component; at least one kind of surfactant and / or co-surfactant, such as hydrogenated castor oil and Transcutol-p, in such amount as to form micro emulsion; and medicinal supplementary material, such as boric acid, borax and sodium bisulfite. The composition is prepared into eye drop or eye gel, and when it is prepared into gel, carbomer is used as the gel matrix. Compared with similar products, the composition of the present invention has high stability, less irritation to eye, capacity of be used to child and other advantages.
Owner:SHENYANG XINGQI PHARM CO LTD
Derivative of macrolides, method for preparing same and application thereof
InactiveCN101624412APromote dissolutionImprove bioavailabilityOrganic active ingredientsSugar derivativesSolubilityPhosphoric acid
The invention provides a derivative of macrolides, a method for preparing the same and application thereof. The derivative is a hydrate of erythrocin and salt, the molecular formula is C37H67NO13.A.nH2O, and n is between 1.0 and 11.0; and A is selected from an organic acid or inorganic acid, and one of lactobionic acid, thiocyanic acid, maleic acid, fumaric acid, thiocyanic acid, acetic acid, methanesulfonic acid, benzene sulfonic acid, nicotinic acid, lactic acid, citric acid, tartaric acid, aspartic acid, glutamic acid and phosphoric acid. The hydrate has better water solubility and storing stability, and is suitably used for preparing medicaments of treating and preventing infectious diseases of human or animals caused due to sensitive bacteria of Gram-positive or negative bacteria.
Owner:刘力
Lactose acidized glycyrrhetinic chitosan material and preparation method and application thereof
ActiveCN102863556AIncrease contentImprove reliabilityPharmaceutical non-active ingredientsPolymer scienceReceptor
The invention relates to a lactose acidized glycyrrhetinic chitosan material and a preparation method and the application thereof. The lactose acidized glycyrrhetinic chitosan material is a glycyrrhetinic acid and lactobionic acid jointly modified chitosan material which is synthesized through N-acylation reaction with chitosan serving as carrier and glycyrrhetinic acid and lactobionic acid serving as ligands. The invention further provides a lactose acidized glycyrrhetinic chitosan / 5-fluorouracil medicine carrying nano particle. The lactose acidized glycyrrhetinic chitosan material and the preparation method and the application thereof have the advantages that the dual-ligand co-modified chitosan material is synthesized for the first time, and the nano particle is prepared for target research; and the lactose acidized glycyrrhetinic chitosan which is prepared into the nano particle has higher liver targeting performance and hepatoma cell receptor mediate initiative targeting performance as compared with GA (glycyrrhetinic acid )-CTS (chitosan) and CTS, distribution in other visceral organs can be evidently reduced, reliability in hepatoma targeting is improved, and the lactose acidized glycyrrhetinic chitosan material can be used as a carrier material which has wide application prospect in clinical hepatoma targeted treatment.
Owner:THE FIFTH PEOPLES HOSPITAL OF SHANGHAI FUDAN UNIV
Moisturizer and preparation technology thereof
ActiveCN108420757AFast absorptionStrong penetrating powerCosmetic preparationsToilet preparationsGlycerolSodium hyaluronate
The invention discloses a moisturizer and a preparation technology thereof, and belongs to the technical field of cosmetics. The moisturizer comprises the following components in parts by weight: 0.1-0.2 part of sodium hyaluronate, 4-5 parts of an alcohol humectant, 2.8-3.5 parts of a first composite humectant, 2.5-3.8 parts of a second composite humectant, 2-3.5 parts of methyl gluceth-20, 10-12parts of a skin toner and 73.62-75.7 parts of pure water, wherein the alcohol humectant comprises at least one of 1, 3-butanediol and 1, 2-hexanediol; the first composite humectant comprises pure water, polyglucuronic acid, mannose, beta-glucan and lactobionic acid; the second composite humectant is a mixture of glycerol and glycerol polyacrylate; the skin toner comprises at least one of a chlorella extract, a diploid yeast fermentation product lysate and a rice fermentation product filtrate. The moisturizer has the advantages of quick moisturizing, a good moisturizing effect and capability ofkeep water and oil balance of skin.
Owner:浙江高妍科技有限公司
Oxidized graphene medicine-carried composite material for liver cancer targeting and preparation method of composite material
InactiveCN104146946AEasy to operateMild experimental conditionsOrganic active ingredientsPharmaceutical delivery mechanismGrapheneHepatic Cancers
The invention relates to an oxidized graphene medicine-carried composite material for liver cancer targeting and a preparation method of the composite material. The obtained composite material is a compound formed by doxorubicin DOX and oxidized graphene GO-PEI-FI-PEG-LA which is modified by a lactobionic acid. The preparation method comprises the following steps: synthesizing the oxidized graphene composite material GO-PEI-FI-PEG-LA; preparing standard doxorubicin curves under the environment with two pH values; dissolving the oxidized graphene composite material in water, adding an aqueous solution of doxorubicin hydrochloride and regulating the pH value to obtain a neutral and alkaline value, stirring for 4 hours, dialyzing, freezing and drying so as to obtain the oxidized graphene medicine-carried composite material. The novel medicine-carried material provided by the invention has the characteristics of pH-sensitive releasing and liver cancer cell targeting, can be applied to anti-tumor researches and has a good practical value.
Owner:DONGHUA UNIV
Acid Addition Salt of Donepezil and Pharmaceutical Composition Thereof
Disclosed is an acid addition salt of donepezil, wherein acid counterion is selected from the group consisting of pamoic acid, cypionic acid, camphor sulfonic acid, enanthic acid, fusidic acid, gluceptic acid, gluconic acid, lactobionic acid, lauric acid, valeric acid, Dibenzoyl-D-Tartaric acid and terephthalic acid. Disclosed is a process for the preparation and pharmaceutical composition comprising the same. More specifically, disclosed is concerned with the pamoate acid addition salts of donepezil. Disclosed also is long acting formulation comprising the acid addition salt of donepezil and process for the preparation thereof.
Owner:TORRENT PHARMA LTD
Gene transfection method based on polyamide arborescent macromolecule carrier
InactiveCN102698290ATargetedMild transfection conditionsGenetic material ingredientsPharmaceutical non-active ingredientsPolyamideGene transfer
The invention relates to a gene transfection method based on a polyamide arborescent macromolecule carrier. The gene transfection method comprises the followings: lactobionic acid decoration to the surface of polyamide arborescent macromolecule to obtain G5. NH2-La; (2), preparation of lactobionic acid decorated polyamide arborescent macromolecule carrier and plasmid compound so as to obtain G5.NH2-La and plasmid compound G5.NH2-La / p DNA; and (3), lactobionic acid decorated polyamide arborescent macromolecule plasmid compound targeting gene transfer and expression to hepatoma carcinoma cells. The functionalized polyamide arborescent macromolecule plays a targeting effect on the hepatoma carcinoma cells; and the gene transfection method provided by the invention has the advantages of temperate transfection conditions, easiness in operation, high transfection efficiency, excellent specificity and the like, and has a wide application prospect.
Owner:DONGHUA UNIV
Preparation method and application of lactobionic acid composite film coating preservative
InactiveCN108157486AEasy to makeKeep the flavorFood ingredient as antioxidantAcidic food ingredientsComposite filmChemistry
The invention discloses a preparation method and application of a lactobionic acid composite film coating preservative. The preparation method comprises the following steps: firstly, preparing the lactobionic acid composite film coating preservative, and then applying the lactobionic acid composite film coating preservative to preservation of chilled fresh meat. The preparation method of the lactobionic acid composite film coating preservative is simple, convenient and easy to popularize, and the composite film liquid prepared by the method is edible, green and environment-friendly and can replace a traditional chemical preservation method. The lactobionic acid composite film coating preservative is applied to preservation of chilled fresh meat; after the chilled fresh meat is soaked in the composite preservative, surface moisture loss, microbial breeding, fat oxidation and increase of volatile salt based nitrogen number of the chilled fresh meat can be decelerated; and the composite preservative also has a certain color protection effect, maintains the specific flavor of the chilled fresh meat and prolongs the shelf life of the chilled fresh meat.
Owner:SHENYANG AGRI UNIV
Preparation method of composite material containing lactobionic acid-modified graphene oxide
The invention relates to a preparation method of a composite material containing lactobionic acid-modified graphene oxide, and the method is as follows: chemically bonding graphene oxide (GO) and PEI (polyethyleneimine) in dimethyl sulfoxide by the effect of activator EDC (1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide), dialyzing, and freeze-drying for synthesis of GO-PEI; dissolving the LA in a phosphate buffer solution, adding EDC and NHS (N-Hydroxysuccinimide) for activation, adding NH2-mPEG-COOH, reacting for 12-24h at room temperature, dialyzing, and freeze-drying to obtain PEG-LA; dissolving the GO-PEI in water, adding a FITC (fluorescein isothiocyanate) solution; adding the EDC and the NHS into the PEG-LA for activation, adding the GO-PEI solution for reaction to obtain GO-PEI-FI-PEG-LA, adding triethylamine for mixing, adding acetic anhydride, reacting at room temperature, dialyzing, and freeze-drying to obtain the graphene oxide composite material. The preparation process of the preparation method is simple, the experimental conditions are normal temperature and pressure, and the preparation method is easy to operate.
Owner:DONGHUA UNIV
Measuring method of pectin content in tobaccos and tobacco products
The invention discloses a measuring method of pectin content in tobaccos and tobacco products, belonging to the technical field of tobacco analysis detection. The measuring method of the pectin content in tobaccos and tobacco products comprises the following steps: (1), adding acidic alcohol liquor into a tobacco sample, then, heating and refluxing, carrying out solid-liquid separation to obtain filtrate and filter residues, and making up to volume after cooling the filtrate to obtain liquor a; (2), adding acetic acid / sodium acetate buffer liquor and pectinase liquor into the filter residues, placing in a water bath for enzymolysis, carrying out suction filtration, and making up to volume to obtain liquor b; (3), getting a certain amount of liquor a, adding the acetic acid / sodium acetate buffer liquor and the pectinase liquor, placing in the water bath for enzymolysis, carrying out suction filtration, transferring the filtrate to a volumetric flask, adding a certain amount of liquor b, making up to volume to obtain to-be-measured liquor; and (4), enabling the to-be-measured liquor to pass through a 0.45-micron filter membrane and then carrying out ion chromatography analysis. The pectin content is calculated in terms of content of lactobionic acid. The measuring method disclosed by the invention is simple to operate, good in repeatability and high in recovery rate, and capable of satisfying batch measurement requirement of pectin content in the tobaccos and the tobacco products.
Owner:HONGTA TOBACCO GRP
Meat based food product comprising lactobionic acid
InactiveUS20090214752A1Water loss upon freezing and subsequent thawing and/or upon cooking is reducedWort preparationAlcoholic beverage preparationEgg Food ProductFood products
The inventor has found that a meat based food product comprising lactobionic acid shows a reduced water loss upon freezing and subsequent thawing and / or upon cooking compared to a similar product without lactobionic add.
Owner:NOVOZYMES AS
Pre-mixed feed for improving bone density and eggshell quality of laying hens and preparation method thereof
InactiveCN109123181APromote absorptionBroaden the formation processFood processingAnimal feeding stuffVitamin K2Eggshell
The invention provides a pre-mixed feed for improving the bone mineral density and eggshell quality and a preparation method thereof, belonging to the technical field of egg chicken feed. The method comprises the following components in parts by weight: 130-170 parts of calcium hydrogen phosphate, 100-160 parts of stone powder, 100-150 parts of shell powder, 10-40 parts of calcium malate, 20-27 parts of calcium hydroxymethionine, 0.5-2 parts of lactobionic acid, 0.5-2 parts of agaricus blazei and 0.5-2 parts of colostrum alkaline protein, 2-5 parts of hydroxyl vitamin D, 2-8 parts of phytase,2-5 parts of composite enzyme preparation, 2-5 parts of microecological agent, 0.1-0.4 parts of soybean flavone, 0.1-0.4 parts of vitamin K2, 0.5-2 parts of bone collagen, 1-4 parts of polydextrose, 0.5-2 parts of fructo-oligosaccharide, 0.5-2 parts of rhizoma drynariae, 0.5-2 parts of fructus psoraleae and the like. In order to improve the calcium utilization rate, a brand new idea of calcium utilization is provided, that is, three systems of the calcium supplement of the laying hens, that is, a calcium supplementing system, a calcium promotion absorption system and a health system of improving the gastrointestinal.
Owner:播恩集团股份有限公司
Liver cancer-targeted multi-walled carbon nanotube drug-loaded composite material and preparation method thereof
InactiveCN103990143AEasy to operateMild experimental conditionsOrganic active ingredientsPharmaceutical non-active ingredientsAlkalinityFreeze-drying
The invention relates to a liver cancer-targeted multi-walled carbon nanotube drug-loaded composite material and a preparation method thereof. The composite material is a compound of doxorubicin (doxorubicin) and a lactobionic acid modified multi-walled carbon nanotube CNT-PEI-FI-PEG-LA. The preparation method comprises the following steps: synthesizing the multi-walled carbon nanotube composite material CNT-PEI-FI-PEG-LA; formulating doxorubicin standard curves in two types of pH value environments; and dissolving the multi-walled carbon nanotube composite material in water, adding a doxorubicin hydrochloride aqueous solution, adjusting the pH value to neutrality and alkalinity, stirring for 4 hours, dialyzing, and carrying out freeze drying, thus obtaining the liver cancer-targeted multi-walled carbon nanotube drug-loaded composite material. The liver cancer-targeted multi-walled carbon nanotube drug-loaded composite material has the characteristics of pH sensitive release and liver cancer cell targeting, can be used for anti-tumor research and has very high practical value.
Owner:DONGHUA UNIV
Cosmetic composition containing gluconolactone and lactobionic acid
ActiveCN104337705AGood moisturizing effectExcellent skin exfoliationSoap detergents with organic compounding agentsCosmetic preparationsMedicineSkin color
The invention relates to a cosmetic composition, and more particularly, provides a cosmetic composition containing Gluconolactone and Lactobiaonic Acid at a specific weight ratio and used for removing keratoderma and whitening skin or having the excellent skin color improving effect.
Owner:LG HOUSEHOLD & HEALTH CARE LTD
Lactobionic acid azithromycin for injections and preparation method thereof
InactiveCN101327191AUniform crystallizationConsistent colorAntibacterial agentsOrganic active ingredientsActivated carbonAzithromycin
The invention provides lactose-azithromycin freeze-dried powder and a preparation method thereof. The freeze-dried powder with simple components only contains main drug component. The preparation method of the lactose-azithromycin freeze-dried powder is that main drug is dissolved in injection water, and then is decolorized and filtered through activated carbon, the filtrate is cooled at 30DEG below zero to 60DEG below zero in a freeze drier to be solidified, and then is heated to 0 DEG to 40 DEG by stages in the condition of high vacuum, meanwhile, freeze-drying curve is controlled strictly, and finally, the lactose-azithromycin freeze-dried powder is obtained. The obtained lactose-azithromycin freeze-dried powder has the advantages of favorable stability and resolubity, etc.
Owner:HAINAN JINRUI PHARMA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com